Drugs / HWS116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07413328 | Apr 2026 → Aug 2027 expected | cancer | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HWS116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07413328 ↗ |
| Route | Intravenous | “Administered intravenous infusion at pre-specified doses every two weeks.” NCT07413328 ↗ |